CPhI Show Daily Podcast Series - Valsynthese - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

CPhI Show Daily Podcast Series - Valsynthese


Valsynthese - Mr. Helmut Zimmerman


Helmut Zimmermann
Commercial Director
Valsynthese

Add this Podcast feed to your media player



Valsynthese is a custom manufacturing organisation concentrating on hazardous and high energetic chemistry. Mr. Zimmermann introduces Valsynthese’s new capabilities in phosgenation, further expanding their tool-box of core competencies in highly energetic reactions. Mr. Zimmerman also delivers quality system updates as well as future plans for compliance beyond approval as API manufacturers in Europe, Asia, South America and Japan. Reducing environmental impact through investment in new recycling facilities is also discussed.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
70%
Breakthrough designations
4%
Protecting the supply chain
17%
Expedited reviews of drug submissions
2%
More stakeholder involvement
7%
View Results
Eric Langerr Outsourcing Outlook Eric LangerTargeting Different Off-Shore Destinations
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerAsymmetric Synthesis Continues to Advance
Jill Wechsler Regulatory Watch Jill Wechsler Data Integrity Key to GMP Compliance
Sean Milmo European Regulatory WatchSean MilmoExtending the Scope of Pharmacovigilance Comes at a Price
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Ebola Outbreak Raises Ethical Issues
Better Comms Means a Fitter Future for Pharma, Part 2: Realizing the Benefits of Unified Communications
Better Comms Means a Fitter Future for Pharma, Part 1: Challenges and Changes

Click here